These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 26050527)
1. Macyranones: Structure, Biosynthesis, and Binding Mode of an Unprecedented Epoxyketone that Targets the 20S Proteasome. Keller L; Plaza A; Dubiella C; Groll M; Kaiser M; Müller R J Am Chem Soc; 2015 Jul; 137(25):8121-30. PubMed ID: 26050527 [TBL] [Abstract][Full Text] [Related]
2. Epoxomicin and Eponemycin Biosynthesis Involves gem-Dimethylation and an Acyl-CoA Dehydrogenase-Like Enzyme. Zettler J; Zubeil F; Kulik A; Grond S; Kaysser L Chembiochem; 2016 May; 17(9):792-8. PubMed ID: 26789439 [TBL] [Abstract][Full Text] [Related]
3. Cystomanamides: structure and biosynthetic pathway of a family of glycosylated lipopeptides from myxobacteria. Etzbach L; Plaza A; Garcia R; Baumann S; Müller R Org Lett; 2014 May; 16(9):2414-7. PubMed ID: 24735013 [TBL] [Abstract][Full Text] [Related]
4. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors. Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686 [TBL] [Abstract][Full Text] [Related]
5. Identifying the Minimal Enzymes Required for Biosynthesis of Epoxyketone Proteasome Inhibitors. Liu J; Zhu X; Zhang W Chembiochem; 2015 Dec; 16(18):2585-9. PubMed ID: 26477320 [TBL] [Abstract][Full Text] [Related]
6. Multiplexed metagenome mining using short DNA sequence tags facilitates targeted discovery of epoxyketone proteasome inhibitors. Owen JG; Charlop-Powers Z; Smith AG; Ternei MA; Calle PY; Reddy BV; Montiel D; Brady SF Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4221-6. PubMed ID: 25831524 [TBL] [Abstract][Full Text] [Related]
7. Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action. Kawamura S; Unno Y; List A; Mizuno A; Tanaka M; Sasaki T; Arisawa M; Asai A; Groll M; Shuto S J Med Chem; 2013 May; 56(9):3689-700. PubMed ID: 23547757 [TBL] [Abstract][Full Text] [Related]
8. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981 [TBL] [Abstract][Full Text] [Related]
9. Development and characterization of proteasome inhibitors. Bo Kim K; Fonseca FN; Crews CM Methods Enzymol; 2005; 399():585-609. PubMed ID: 16338383 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome. Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024 [TBL] [Abstract][Full Text] [Related]
12. α- and β-hydrazino acid-based pseudopeptides inhibit the chymotrypsin-like activity of the eukaryotic 20S proteasome. Bordessa A; Keita M; Maréchal X; Formicola L; Lagarde N; Rodrigo J; Bernadat G; Bauvais C; Soulier JL; Dufau L; Milcent T; Crousse B; Reboud-Ravaux M; Ongeri S Eur J Med Chem; 2013; 70():505-24. PubMed ID: 24185380 [TBL] [Abstract][Full Text] [Related]
13. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome. Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790 [TBL] [Abstract][Full Text] [Related]
14. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors. Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors. Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Groll M; Huber R Biochim Biophys Acta; 2004 Nov; 1695(1-3):33-44. PubMed ID: 15571807 [TBL] [Abstract][Full Text] [Related]
17. Structure-based design of human immuno- and constitutive proteasomes inhibitors. Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive mass spectrometric analysis of the 20S proteasome complex. Huang L; Burlingame AL Methods Enzymol; 2005; 405():187-236. PubMed ID: 16413316 [TBL] [Abstract][Full Text] [Related]
19. Peptido sulfonyl fluorides as new powerful proteasome inhibitors. Brouwer AJ; Jonker A; Werkhoven P; Kuo E; Li N; Gallastegui N; Kemmink J; Florea BI; Groll M; Overkleeft HS; Liskamp RM J Med Chem; 2012 Dec; 55(24):10995-1003. PubMed ID: 23170994 [TBL] [Abstract][Full Text] [Related]
20. Indolo-phakellins as β5-specific noncovalent proteasome inhibitors. Beck P; Lansdell TA; Hewlett NM; Tepe JJ; Groll M Angew Chem Int Ed Engl; 2015 Feb; 54(9):2830-3. PubMed ID: 25581903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]